title: Low dose liraglutide in Indian patients with type 2 diabetes in the real world setting.
abstract: Liraglutide, a human glucagon-like peptide-1 receptor agonist, decreases glycosylated hemoglobin and causes weight loss. However, the cost of therapy and gastrointestinal side- effects such as nausea and diarrhea are important impediments to adherence and long-term compliance. We assessed the efficacy, safety and tolerability of low dose (0.6 mg) liraglutide in obese uncontrolled longstanding type 2 diabetes in Indian patients. Low dose liraglutide improved glycemic control and decreased weight. However, there was a significant drop out because of gastrointestinal intolerance and financial constraints.
authors.affiliation: Department of Endocrinology, KPC Medical College, Kolkata, West Bengal, India ; Department of Endocrinology, RTIICS, Kolkata, West Bengal, India.
authors.forename: Debmalya
authors.initials: D
authors.lastname: Sanyal
authors.forename: Anirban
authors.initials: A
authors.lastname: Majumdar
keywords: India; liraglutide; type 2 diabetes